-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in Hong Kong stocks | Yingpai Pharmaceutical-B (07630) reversed the market and rose more than 15%. Senapali was approved by the European Union to be listed for maintenance treatment of the entire population on the frontline of ovarian cancer

Zhitongcaijing·11/19/2026 02:33:03
Listen to the news

The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) reversed the market and rose more than 15%. As of press release, it rose 11.85% to HK$9.295, with a turnover of HK$53.443 million.

According to the news, on November 17, Yingpai Pharmaceutical announced that the innovative drug Senapali (Sepalna®, overseas trade name Sepalna®) developed independently by the company has officially obtained a final decision from the European Commission to approve it for maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

This approval was officially made after the European Medicines Agency's Committee on Medicines for Human Use (CHMP) issued a positive opinion. As a result, senapalil became the first first-line maintenance PARP inhibitor for advanced ovarian cancer in China to be approved and marketed by the European Union, marking another breakthrough for domestically produced innovative drugs targeting ovarian cancer in the European market.